Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis

被引:76
|
作者
Sanguineti, Roberta [1 ]
Puddu, Alessandra [1 ]
Mach, Francois [2 ]
Montecucco, Fabrizio [2 ,3 ,4 ]
Viviani, Giorgio Luciano [1 ]
机构
[1] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy
[2] Univ Hosp Geneva, Fac Med, Fdn Med Res, Div Cardiol, CH-1211 Geneva, Switzerland
[3] Univ Genoa, IRCCS Azienda Osped Univ San Martino, IST Ist Nazl Ric Canc, Dept Internal Med,Sch Med,Clin Internal Med 1, I-16132 Genoa, Italy
[4] Univ Hosp Geneva, Div Lab Med, Dept Genet & Lab Med, CH-1205 Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
NITROGEN-CONTAINING BISPHOSPHONATE; LEUKEMIA INHIBITORY FACTOR; BONE-MINERAL DENSITY; NONENZYMATIC GLYCATION; I COLLAGEN; CROSS-LINKING; EXTRACELLULAR-MATRIX; OSTEOBLAST APOPTOSIS; SIGNALING PATHWAYS; RANKL EXPRESSION;
D O I
10.1155/2014/975872
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Osteoporosis is a major public health burden that is expected to further increase as the global population ages. In the last twenty years, advanced glycation end products (AGEs) have been shown to be critical mediators both in the pathogenesis and development of osteoporosis and other chronic degenerative diseases related to aging. The accumulation of AGEs within the bone induces the formation of covalent cross-links with collagen and other bone proteins which affects the mechanical properties of tissue and disturbs bone remodelling and deterioration, underlying osteoporosis. On the other hand, the gradual deterioration of the immune system during aging (defined as immunosenescence) is also characterized by the generation of a high level of oxidants and AGEs. The synthesis and accumulation of AGEs (both localized within the bone or in the systemic circulation) might trigger a vicious circle (in which inflammation and aging merged in the word "Inflammaging") which can establish and sustain the development of osteoporosis. This narrative review will update the molecular mechanisms/pathways by which AGEs induce the functional and structural bone impairment typical of osteoporosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Advanced glycation end products: Detection and reversal
    Al-Abed, Y
    Kapurniotu, A
    Bucala, R
    AMYLOID, PRIONS, AND OTHER PROTEIN AGGREGATES, 1999, 309 : 152 - 172
  • [32] Advanced glycation end products and diabetic retinopathy
    Ross Milne
    Seymour Brownstein
    Amino Acids, 2013, 44 : 1397 - 1407
  • [33] Advanced glycation end products, diabetes and ageing
    Nass, N.
    Bartling, B.
    Santos, A. Navarrete
    Scheubel, R. J.
    Boergermann, J.
    Silber, R. E.
    Simm, A.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2007, 40 (05): : 349 - 356
  • [34] Advanced Glycation End Products and Diabetic Retinopathy
    Chen, M.
    Curtis, T. M.
    Stitt, A. W.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (26) : 3234 - 3240
  • [35] Advanced glycation end products, diabetes, and the brain
    Coker, Laura H.
    Wagenknecht, Lynne E.
    NEUROLOGY, 2011, 77 (14) : 1326 - 1327
  • [36] ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSIS
    Triginer, L.
    Tio, L.
    Carrion, I.
    Guillen-Del-Castillo, A.
    Ribes, A.
    Valencia Muntala, L.
    Monfort, J.
    Salman, T. C.
    Pros, A.
    Narvaez, J.
    Simeon Aznar, C. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1655 - 1656
  • [37] Advanced glycation end products, dementia, and diabetes
    Lovestone, Simon
    Smith, Ulf
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (13) : 4743 - 4744
  • [38] Role of dietary advanced glycation end products
    Clifton, Peter
    Keogh, Jennifer
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (06) : 514 - 515
  • [39] Zinc against advanced glycation end products
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    Maleki, Vahid
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2018, 45 (06) : 491 - 498
  • [40] Advanced glycation end products and diabetic complications
    Stitt, AW
    Jenkins, AJ
    Cooper, ME
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) : 1205 - 1223